Unusual substitutions in HIV-1 Vif from children infected perinatally without progression to AIDS for more than 8 years without therapy

Journal of Medical Virology

Volumn 84, Issue 12, 2012, Pages 1844-1852

  De Maio, Federico A ^a   Rocco, Carlos A ^a   Aulicino, Paula C ^a   Bologna, Rosa ^a   Mangano, Andrea ^a   Sen, Luisa ^a  

^a Hospital de Pediatria SAMIC Prof Dr Juan P Garrahan   (Argentina)

Author keywords

HIV 1; Pediatric AIDS; Slow progression; Vif

Indexed keywords

VIF PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; COMPARATIVE STUDY; DISEASE COURSE; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PERINATAL INFECTION; PHYLOGENY; PROTEIN FUNCTION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; CHILD; CHILD, PRESCHOOL; CYTIDINE DEAMINASE; DATABASES, GENETIC; DISEASE PROGRESSION; FEMALE; GENES, VIRAL; GENETIC VARIATION; GENOTYPING TECHNIQUES; HIV-1; HUMANS; INFANT; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MALE; MOLECULAR SEQUENCE DATA; MUTATION; PHYLOGENY; PROTEIN STRUCTURE, TERTIARY; TIME FACTORS; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VIRAL LOAD; VIRUS REPLICATION;

EID: 84867700315     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23261     Document Type: Article

References (35)

1. Adekale MA, Cane PA, McCrae MA. 2005. Changes in the Vif protein of HIV-1 associated with the development of resistance to inhibitors of viral protease. J Med Virol 75:195-201.
2. Albin JS, Harris RS. 2010. Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: Implications for therapeutics. Expert Rev Mol Med 12:e4.
3. Alexander L, Aquino-DeJesus MJ, Chan M, Andiman WA. 2002. Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by a two-amino-acid insertion in HIV-1 Vif from a nonprogressing mother and child. J Virol 76:10533-10539.
4. Alexander L, Cuchura L, Simpson BJ, Andiman WA. 2006. Virologic and host characteristics of human immunodeficiency virus type 1-infected pediatric long term survivors. Pediatr Infect Dis J 25:135-141.
5. Berk DR, Falkovitz-Halpern MS, Hill DW, Albin C, Arrieta A, Bork JM, Cohan D, Nilson B, Petru A, Ruiz J, Weintrub PS, Wenman W, Maldonado YA, California Pediatric HIV Study Group. 2005. Temporal trends in early clinical manifestations of perinatal HIV infection in a population-based cohort. JAMA 293:2221-2231.
6. Caldwell MB, Oxtoby MJ, Simonds RJ, Lindegren ML, Rogers MF. 1994. 1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR 43:1-10.
7. Casartelli N, Di Matteo G, Argentini C, Cancrini C, Bernardi S, Castelli G, Scarlatti G, Plebani A, Rossi P, Doria M. 2003. Structural defects and variations in the HIV-1 nef gene from rapid, slow and non-progressor children. AIDS 17:1291-1301.
8. Dang Y, Davis RW, York IA, Zheng YH. 2010a. Identification of 81LGxGxxIxW89 and 171EDRW174 domains from human immunodeficiency virus type 1 Vif that regulate APOBEC3G and APOBEC3F neutralizing activity. J Virol 84:5741-5750.
9. Dang Y, Wang X, York IA, Zheng YH. 2010b. Identification of a critical T(Q/D/E)x5ADx2(I/L) motif from primate lentivirus Vif proteins that regulate APOBEC3G and APOBEC3F neutralizing activity. J Virol 84:8561-8570.
10. De Maio FA, Rocco CA, Aulicino PC, Bologna R, Mangano A, Sen L. 2011. Effect of HIV-1 Vif variability on progression to pediatric AIDS and its association with APOBEC3G and CUL5 polymorphisms. Infect Genet Evol 11:1256-1262.
11. DeHart JL, Bosque A, Harris RS, Planelles V. 2008. Human immunodeficiency virus type 1 Vif induces cell cycle delay via recruitment of the same E3 ubiquitin ligase complex that targets APOBEC3 proteins for degradation. J Virol 82:9265-9272.
12. Farrow MA, Somasundaran M, Zhang C, Gabuzda D, Sullivan JL, Greenough TC. 2005. Nuclear localization of HIV type 1 Vif isolated from a long-term asymptomatic individual and potential role in virus attenuation. AIDS Res Hum Retroviruses 21:565-574.
13. Gonzalez E, Kulkarni H, Bolivar H, Mangano A, Sanchez R, Catano G, Nibbs RJ, Freedman BI, Quinones MP, Bamshad MJ, Murthy KK, Rovin BH, Bradley W, Clark RA, Anderson SA, O'connell RJ, Agan BK, Ahuja SS, Bologna R, Sen L, Dolan MJ, Ahuja SK. 2005. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science 307:1434-1440.
14. Hassaine G, Agostini I, Candotti D, Bessou G, Caballero M, Agut H, Autran B, Barthalay Y, Vigne R. 2000. Characterization of human immunodeficiency virus type 1 vif gene in long-term asymptomatic individuals. Virology 276:169-180.
15. He Z, Zhang W, Chen G, Xu R, Yu XF. 2008. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction. J Mol Biol 381:1000-1011.
16. Henriet S, Mercenne G, Bernacchi S, Paillart JC, Marquet R. 2009. Tumultuous relationship between the human immunodeficiency virus type 1 viral infectivity factor (Vif) and the human APOBEC-3G and APOBEC-3F restriction factors. Microbiol Mol Biol Rev 73:211-232.
17. Honeyborne I, Prendergast A, Pereyra F, Leslie A, Crawford H, Payne R, Reddy S, Bishop K, Moodley E, Nair K, van der Stok M, McCarthy N, Rousseau CM, Addo M, Mullins JI, Brander C, Kiepiela P, Walker BD, Goulder PJ. 2007. Control of human immunodeficiency virus type 1 is associated with HLA-B*13 and targeting of multiple gag-specific CD8+ T-cell epitopes. J Virol 81:3667-3672.
18. Kataropoulou A, Bovolenta C, Belfiore A, Trabatti S, Garbelli A, Porcellini S, Lupo R, Maga G. 2009. Mutational analysis of the HIV-1 auxiliary protein Vif identifies independent domains important for the physical and functional interaction with HIV-1 reverse transcriptase. Nucleic Acids Res 37:3660-3669.
19. Land AM, Ball TB, Luo M, Pilon R, Sandstrom P, Embree JE, Wachihi C, Kimani J, Plummer FA. 2008. Human immunodeficiency virus (HIV) type 1 proviral hypermutation correlates with CD4 count in HIV-infected women from Kenya. J Virol 82:8172-8182.
20. Mangano A, Kopka J, Batalla M, Bologna R, Sen L. 2000. Protective effect of CCR2-64I and not of CCR5-delta32 and SDF1-3′A in pediatric HIV-1 infection. J Acquir Immune Defic Syndr 23:52-57.
21. Mercenne G, Bernacchi S, Richer D, Bec G, Henriet S, Paillart JC, Marquet R. 2010. HIV-1 Vif binds to APOBEC3G mRNA and inhibits its translation. Nucleic Acids Res 38:633-646.
22. Misrahi M, Teglas JP, N'Go N, Burgard M, Mayaux MJ, Rouzioux C, Delfraissy JF, Blanche S. 1998. CCR5 chemokine receptor variant in HIV-1 mother-to-child transmission and disease progression in children. French Pediatric HIV Infection Study Group. JAMA 279:277-280.
23. Okumura A, Alce T, Lubyova B, Ezelle H, Strebel K, Pitha PM. 2008. HIV-1 accessory proteins VPR and Vif modulate antiviral response by targeting IRF-3 for degradation. Virology 373:85-97.
24. Pace C, Keller J, Nolan D, James I, Gaudieri S, Moore C, Mallal S. 2006. Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation. J Virol 80:9259-9269.
25. Rangel HR, Garzaro D, Rodríguez AK, Ramírez AH, Ameli G, Del Rosario Gutiérrez C, Pujol FH. 2009. Deletion, insertion and stop codon mutations in vif genes of HIV-1 infecting slow progressor patients. J Infect Dev Ctries 3:531-538.
26. Russell RA, Pathak VK. 2007. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J Virol 81:8201-8210.
27. Sakai K, Dimas J, Lenardo MJ. 2006. The Vif and Vpr accessory proteins independently cause HIV-1-induced T cell cytopathicity and cell cycle arrest. Proc Natl Acad Sci USA 103:3369-3374.
28. Sandonís V, Casado C, Alvaro T, Pernas M, Olivares I, García S, Rodríguez C, del Romero J, López-Galíndez C. 2009. A combination of defective DNA and protective host factors are found in a set of HIV-1 ancestral LTNPs. Virology 391:73-82.
29. Singh KK, Gray PK, Wang Y, Fenton T, Trout RN, Spector SA. 2011. HLA alleles are associated with altered risk for disease progression and central nervous system impairment of HIV-infected children. J Acquir Immune Defic Syndr 57:32-39.
30. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. 2011. MEGA5: Molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 28:2731-2739.
31. Tang Y, Huang S, Dunkley-Thompson J, Steel-Duncan JC, Ryland EG, St John MA, Hazra R, Christie CD, Feeney ME. 2010. Correlates of spontaneous viral control among long-term survivors of perinatal HIV-1 infection expressing human leukocyte antigen-B57. AIDS 24:1425-1435.
32. Tresoldi E, Romiti ML, Boniotto M, Crovella S, Salvatori F, Palomba E, Pastore A, Cancrini C, de Martino M, Plebani A, Castelli G, Rossi P, Tovo PA, Amoroso A, Scarlatti G, European Shared Cost Project Group, Italian Register for HIV Infection in Children. 2002. Prognostic value of the stromal cell-derived factor 1 3′A mutation in pediatric human immunodeficiency virus type 1 infection. J Infect Dis 185:696-700.
33. Yedavalli VR, Ahmad N. 2001. Low conservation of functional domains of HIV type 1 vif and vpr genes in infected mothers correlates with lack of vertical transmission. AIDS Res Hum Retroviruses 17:911-923.
34. Yedavalli VR, Chappey C, Matala E, Ahmad N. 1998. Conservation of an intact vif gene of human immunodeficiency virus type 1 during maternal-fetal transmission. J Virol 72:1092-1102.
35. Zhao Y, Chen M, Wang B, Yang J, Elder RT, Song XQ, Yu M, Saksena NK. 2002. Functional conservation of HIV-1 Vpr and variability in a mother-child pair of long-term non-progressors. Virus Res 89:103-121.